scholarly article | Q13442814 |
P50 | author | Xinyong Liu | Q75661546 |
P2093 | author name string | Peng Zhan | |
Dongwei Kang | |||
Yu'ning Song | |||
Wenmin Chen | |||
P2860 | cites work | Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups | Q24611024 |
Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones | Q24798680 | ||
Fragment screening and HIV therapeutics | Q26826945 | ||
Novel therapeutic strategies targeting HIV integrase | Q27003960 | ||
HIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel Site | Q27640888 | ||
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays | Q27653562 | ||
Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase | Q27657535 | ||
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information | Q27657612 | ||
Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes | Q27658013 | ||
Structure of HIV-1 Reverse Transcriptase with the Inhibitor β-Thujaplicinol Bound at the RNase H Active Site | Q27658584 | ||
Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of action | Q27659605 | ||
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site | Q27660224 | ||
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication | Q27661671 | ||
Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors | Q27661750 | ||
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 | Q27663609 | ||
Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1 | Q27666603 | ||
Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket | Q27667348 | ||
Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors | Q27667421 | ||
Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H | Q27667836 | ||
Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design | Q27667923 | ||
Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening | Q27675974 | ||
Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase | Q27676777 | ||
Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV Protease | Q27677124 | ||
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation | Q27677515 | ||
Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors | Q27678141 | ||
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action | Q27678745 | ||
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization | Q27684133 | ||
Structure-Based Design of 2-Aminopyridine Oxazolidinones as Potent and Selective Tankyrase Inhibitors | Q27684184 | ||
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors | Q27684686 | ||
Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase | Q39613869 | ||
5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity. | Q39746338 | ||
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate | Q39800337 | ||
Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase | Q39889724 | ||
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis | Q40423448 | ||
HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. | Q41879018 | ||
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy | Q42537068 | ||
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase | Q42549637 | ||
Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitors | Q42712159 | ||
Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors | Q42712397 | ||
Discovery of small molecule HIV-1 integrase dimerization inhibitors | Q42719255 | ||
Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold | Q42876787 | ||
Pyrazole NNRTIs 3: optimisation of physicochemical properties | Q43283624 | ||
Pyrazole NNRTIs 1: design and initial optimisation of a novel template | Q43285390 | ||
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid | Q44248249 | ||
A novel mechanism for inhibition of HIV-1 reverse transcriptase | Q44365269 | ||
Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides | Q44829634 | ||
6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro | Q44897779 | ||
Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors | Q45157847 | ||
Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis | Q45177265 | ||
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor | Q45586245 | ||
Complexes of HIV-1 integrase with HAT proteins: multiscale models, dynamics, and hypotheses on allosteric sites of inhibition. | Q46010779 | ||
Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase | Q46346735 | ||
D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. | Q46437340 | ||
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance | Q46504568 | ||
A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs | Q46849623 | ||
Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. | Q53348127 | ||
Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase. | Q54564921 | ||
Lethal mutagenesis of HIV. | Q36008905 | ||
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors | Q36276790 | ||
Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. | Q36300994 | ||
Allosteric inhibition of HIV-1 integrase activity | Q36920004 | ||
Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases | Q36928605 | ||
Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer. | Q36928993 | ||
Recent advances in the research of HIV-1 RNase H inhibitors | Q37294454 | ||
Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. | Q37432679 | ||
Designed multiple ligands: an emerging anti-HIV drug discovery paradigm | Q37515905 | ||
Molecular basis of human immunodeficiency virus drug resistance: an update. | Q37555266 | ||
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update | Q37581700 | ||
Design strategies of novel NNRTIs to overcome drug resistance | Q37595588 | ||
Kinetic target-guided synthesis | Q37716658 | ||
Cosalane and its analogues: a unique class of anti-HIV agents | Q37764371 | ||
Targeting protein-protein interactions: a promising avenue of anti-HIV drug discovery | Q37780233 | ||
HIV-1 RT-Associated RNase H Function Inhibitors: Recent Advances in Drug Development | Q37790713 | ||
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). | Q37860335 | ||
HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design | Q37869442 | ||
Recent developments of peptidomimetic HIV-1 protease inhibitors | Q37921839 | ||
Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. | Q38081000 | ||
Rationally designed multitarget anti-HIV agents | Q38081542 | ||
Click chemistry for drug development and diverse chemical-biology applications. | Q38093289 | ||
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update | Q38155891 | ||
"Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining | Q38180459 | ||
Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance | Q38299698 | ||
Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. | Q38339368 | ||
The pharmacology of HIV drug resistance | Q39133627 | ||
Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors | Q39140673 | ||
Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction | Q39187770 | ||
Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions | Q39212927 | ||
Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization | Q39337204 | ||
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity | Q39346109 | ||
4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process | Q39504985 | ||
Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization. | Q39555479 | ||
Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function | Q39583211 | ||
Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins | Q27687498 | ||
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate | Q28250395 | ||
Lethal mutagenesis of HIV with mutagenic nucleoside analogs | Q28369649 | ||
Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. | Q30342229 | ||
LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity | Q30399011 | ||
Rapid Diversity‐Oriented Synthesis in Microtiter Plates for In Situ Screening of HIV Protease Inhibitors | Q31024145 | ||
High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations | Q33218516 | ||
Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamide | Q33308195 | ||
Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity | Q33373484 | ||
Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. | Q33476232 | ||
An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule | Q33488152 | ||
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction | Q33635875 | ||
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. | Q33900441 | ||
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. | Q33900459 | ||
Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. | Q33907525 | ||
Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies | Q33945786 | ||
Combining biophysical screening and X-ray crystallography for fragment-based drug discovery | Q33991624 | ||
From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease | Q34081415 | ||
Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. | Q34122562 | ||
Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development | Q34226132 | ||
Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. | Q34350400 | ||
Recent progress in the research of small molecule HIV-1 RNase H inhibitors | Q34398645 | ||
Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays. | Q34436597 | ||
Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold. | Q34439041 | ||
Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series | Q34643481 | ||
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase | Q34645420 | ||
6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase | Q34762297 | ||
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase | Q34770674 | ||
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site | Q34772524 | ||
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase | Q34779869 | ||
5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. | Q35000909 | ||
Allosteric inhibitor development targeting HIV-1 integrase | Q35046515 | ||
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action | Q35185934 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1998-2022 | |
P577 | publication date | 2014-08-01 | |
P1433 | published in | Molecular BioSystems | Q3319467 |
P1476 | title | "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets | |
P478 | volume | 10 |
Q26777448 | Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors |
Q47612838 | Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. |
Q38843215 | Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach |
Q36164152 | First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach |
Q38587368 | Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities |
Q40106207 | Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. |
Q88641336 | Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia |
Q38662691 | Medicinal chemistry insights in the discovery of novel LSD1 inhibitors |
Q38260066 | Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014). |
Q40618808 | Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. |
Q58760446 | Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase |
Q41534943 | Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections |
Search more.